Fig. S1. Expression of CD137 ligand (CD137L) and membrane-bound interleukin (mbIL)-21 on the surface of engineered K562 cells. A: CD137L staining; B: mbIL-21 staining.


Fig. S2. Effects of JSI-124 on natural killer (NK) cells. A: Expression level and phosphorylation status of signal transducer and activator of transcription-3 (STAT-3) in primary natural killer (NK) cells after treatment with 20 ng/ml of interleukin (IL)-21 in the presence or absence of 0·1 μM JSI-124 for 24 h. B: NK cell viability was evaluated by fluorescence activated cell sorter (FACS) after different doses of JSI-124 treatment at different time-points. This was representative of three independent primary NK cells. Results were repeated with three independent expanded NK cells, and similar results were obtained.


Fig. S3. Signal transducer and activator of transcription-3 (STAT-3) inhibition impaired expression of natural killer (NK) cell receptors. NK cells were initially expanded for 2 weeks as described in Materials and methods, and then 1 × 107 expanded NK cells were continued to expand in the presence or absence of 0·1 μM JSI-124. Three days later, the expression of NK cell receptors was detected by fluorescence activated cell sorter (FACS). The percentage decrease was calculated by comparing the mean expression levels of JSI-124-treated cells to those of the untreated control cells; n = 4.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.